Fischer Medical Ventures Ltd
Fischer Medical Ventures Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Fischer Medical Ventures Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
The provided pages of the investor presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor details on year-on-year changes. The investor presentation does not explicitly provide any figures for EBITDA, operating margin, or profit (PAT) for the quarter, nor does it report year-on-year changes or state any explicit margin outlook.
From Fischer Medical Ventures Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
Profitability & Margins
See what Fischer Medical Ventures Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fischer Medical Ventures Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Fischer Medical Ventures Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹101 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fischer Medical Ventures Ltd's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Molbio Diagnosti (Q1 FY27)
Capacity utilization currently at ~58% for test kits and ~42% for devices; automation capex will double revenue capacity with minimal new investment. Key…
- QMS Medical (Q1 FY27)
Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…
- Laxmi Dental (Q1 FY27)
PAT grew 23.8% y-o-y in Q1 FY27, showing healthy bottom-line growth (Page 4). Key concall takeaways from Laxmi Dental Ltd's Q1 FY27 earnings call — and how it…
- Prevest Denpro Ltd (Q1 FY27)
Digital dentistry revenue, especially 3D printing resins, grew 40% this year; 3D printer sales rose by 162%, indicating strong growth potential, with plans for…
Frequently Asked Questions
What were Fischer Medical Ventures Ltd Q1 FY27 results?
The provided pages of the investor presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor details on year-on-year changes. The investor presentation does not explicitly provide any figures for EBITDA, operating margin, or profit (PAT) for the quarter, nor does it report year-on-year changes or state any explicit margin outlook.
What is Fischer Medical Ventures Ltd share price analysis?
Fischer Medical Ventures Ltd currently shows a neutral. The stock trades at a P/E of 94.6 with a market cap of ₹2,316 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fischer Medical Ventures Ltd planning capital expenditure?
The provided pages of the investor presentation (up to page 12) do not explicitly mention any capex details, capacity expansion plans, or new plant/project specifics including amounts, status, or timelines.
Keep Fischer Medical Ventures Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.